Brickroad
Brickroad
IndexSignalsBlog
/Index//

Product

  • Information Frontier Agent
  • Vendor Management Agent
  • Product Tour
  • Pricing

Solutions

  • All Solutions
  • Atlas
  • Wayfinder
  • Horizon

Suppliers

  • Sell Your Data
  • Start Onboarding
  • Programmatic Data License

Community

  • Public Index
  • Signals
  • Blog

Company

  • About
  • Team
  • Careers
  • Brand

Connect

  • LinkedIn
  • X
PrivacyTermsCookies

© 2026 Brickroad

/Index/InsightRX/InsightRX
I

InsightRX

INSIGHTRXManage supplier listing

Real-world observational pharmacokinetic dataset generated by bedside precision dosing: for every dosed patient episode, the patient characteristics and laboratory values used to individualise therapy, measured drug concentrations, the dose actually administered, the model's predicted exposure and recommended dose, and the resulting target attainment or adverse event. Two layers make this unusually valuable. First, it is field dosing data rather than trial data — dosing decisions and concentrations for real patients in real hospitals, including the special populations (renal impairment, obesity, critical illness, paediatrics) that trials systematically exclude and that drug labels most often lack dosing guidance for. Second, a human-in-the-loop layer: each model dose recommendation carries the clinician's decision to accept or override it, and the platform's continuous-learning process uses accumulated outcomes to retrain the dosing models, so the corpus is already curated at model grade rather than raw.

Open buyer room →
InsightRX/InsightRX
SampleCoverage

Sample

Brickroad customers

Sample this dataset before you buy it.

Your sourcing agent asks InsightRX and files the sample in your catalog — private to you.

Start 7-day trial→Nothing is charged until the trial ends.

Coverage

Universe, instruments and categories.

Industry
BiotechnologyHealth Care Technology
Instruments
equities
Categories
Alternative
Reference
Sentiment
Regions
US
Sample tickers
PFEMRKLLYABBVGSKAZNAMGNVRTX
Dataset card
Type
not stated
Format
Structured longitudinal clinical records — patient and episode attributes, laboratory and drug-concentration measurements, dose administration events, model-predicted exposures, and coded outcomes and adverse events — integrated from electronic health records, laboratory systems and flat files, and exposed both as analytic tables supporting pharmacokinetic and pharmacodynamic modelling and simulation and as a natural-language query layer, so the archive also carries a corpus of plain-language clinical analytic questions bound to their resolved queries
Volume
No vendor-stated totals. Structurally implies 1-20M dosing episodes across deployed institutions to date, each carrying a dense multi-point record — patient attributes, laboratory panel, measured concentrations, recommended and administered doses, and outcome — so roughly 20-150M discrete clinical observations. The scarcest component, and the one worth pricing, is measured drug-concentration-plus-dose tuples: an estimated 1-10M pairs, since these require therapeutic drug monitoring to have been ordered and represent the true pharmacokinetic ground truth. All figures inferred from institutional scale and dosing cadence, not published.
Users
Client-side: an estimated 20-100 health-system institutions and roughly 2,000-15,000 named clinician and pharmacist users, inferred from about $3.6M revenue at enterprise health-system contract values across a 33-person company. Data subjects are the asset and are far more numerous: every dosed patient episode at every deployed institution contributes records, so patient volume is an order of magnitude above user count. The analytics product is explicitly designed for clinicians, department leads, directors and executives, indicating multi-role deployment per institution.
History
10 years
Update frequency
not stated
Growth
Active and research-intensive, still early commercial stage — the firm holds a patented process for continuous model retraining, runs a published scientific-publication programme, and has extended beyond provider-facing clinical tools into a dedicated life-sciences line for pharmacokinetic and pharmacodynamic modelling and simulation plus clinical-trial use, which indicates product-line expansion rather than maintenance. At a 33-person headcount with roughly $12.8M raised and roughly $3.6M revenue, it remains venture-stage and commercially early, so growth is capability-driven rather than scale-driven.
Launched
~2015-2017 for the precision-dosing product. The company record carries an organizational identifier from mid-2015, and the presence of issued patents, a peer-reviewed publication record and an established health-system install base implies several years of prior development and deployment. The life-sciences product line is materially newer, an estimated 2021-2023, reflecting a deliberate extension from provider tooling into pharma-facing capability. No founding or launch year is stated on the retrieved page.
Delivery
not stated
Entity mapping
not stated
Sample
not stated
Point-in-time
not stated
Licence
not stated

supplier index read from their site

InsightRX has not added their own details yet. Not yet on file:

  • Dataset
  • Data dictionary
  • Coverage
  • Provenance
  • Rights & data handling